Shots:
- Adlai Nortye has dosed the first patient in the US with AN9025 in its ongoing P-I trial for the treatment of advanced or metastatic solid tumors harboring RAS mutations
- Trial is being conducted by Adlai Nortye with ASK Pharm as a multi-regional study under a license agreement granting Adlai Nortye ex-China rights to AN9025, while ASK Pharm holds rights in mainland China, Hong Kong, & Macao
- AN9025 is an oral small-molecule pan-RAS(ON) inhibitor, targeting a broad range of RAS mutations, & has shown potent, durable preclinical efficacy in pancreatic, lung, & colorectal cancers
Ref: Adlai Nortye| Image: Adlai Nortye|Press Release
Related News: Adlai Nortye Licenses AN9025 to ASK Pharm in a ~$230M Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
